MBI/Mallinckrodt Optison is second ultrasound contrast agent approved after Albunex.
This article was originally published in The Gray Sheet
Executive Summary
MALLINCKRODT/MBI's OPTISON SECOND-GENERATION ECHOCARDIOGRAPHY AGENT APPROVED by FDA Dec. 31. Molecular Biosystems Inc. and Mallinckrodt already market Albunex in the U.S.; like Albunex, Optison uses human albumin microspheres to enhance the contrast of ultrasound scans.